Across TCGA pan-cancer cohorts, KRT17P5 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of KRT17P5’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where KRT17P5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRT17P5 is over-expressed in tumor, although a few such as CHOL and COAD show the opposite, repressed pattern.

KIRC, CHOL, and PAAD are the cancer types where KRT17P5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT17P5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	III,IV	+0.010	.008	7	view →
CHOL	All	All	−0.052	.016	2	view →
PAAD	Male	All	+0.045	.012	2	view →
COAD	All	All	−0.004	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KRT17P5 RNA expression & survival · all KRT17P5 data types